Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
CA 2442684 C · Owner: The University Of Chicago · Inventors: Walsh-Reitz, Margaret; Martin, Terrence E.; Toback, F. Gary
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel group of gastrokines called Gastric Antrum Mucosal Protein is characterized. A member of the group is designated AMP-18. AMP-18 genomic DNA cDNA and the AMP-18 protein are sequenced for human mouse and pig. The AMP-18 , protein and active peptides derived from it are cellular growth factors. Surprisingly, peptides capable of inhibiting the effects of the complete protein, are also derived from the AMP-18 protein. Cytoprotection and control of mammalian gastro-intestinal tissue growth and repair (restitution) is facilitated by the use of the proteins making the protein candidates for , therapies in inflammatory bowel disease and gastric ulcers.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 29, 2002 and granted November 19, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.